Loading clinical trials...
Loading clinical trials...
Perioperative Risk Factors and Nomograms for Participants With Hepatocellular Carcinoma Receiving Neoadjuvant Immunotherapy or Conversion Therapy
Conditions
Locations
1
China
Qilu hospital of Shandong university
Jinan, Shandong, China
Start Date
April 1, 2014
Primary Completion Date
August 1, 2025
Completion Date
August 3, 2026
Last Updated
August 26, 2024
NCT07528066
NCT05689463
NCT06488950
NCT05098197
NCT06230471
NCT07273708
Lead Sponsor
Qilu Hospital of Shandong University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions